IMPAX Sued Based on ANDA for Generic Flomax ®

July 22, 2008

HAYWARD, Calif.--(BUSINESS WIRE)--IMPAX Laboratories, Inc. today announced Boehringer Ingelheim Pharmaceuticals Inc. (Boehringer) and Astellas Pharma Inc. (Astellas) have filed suit for patent infringement in the United States District Court for the Northern District of California based on the Companys submission of Abbreviated New Drug Application (ANDA) for tamsulosin hydrochloride capsules (0.4 mg), generic of Flomax®, to the Food and Drug Administration. In connection with this ANDA, IMPAX provided notice to Boehringer and Astellas that its submission includes a Paragraph IV certification stating the Company believes its product does not infringe any valid or enforceable claim of U.S. Patent No. 4,703,063.

Flomax® capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia. According to Wolters Kluwer Health, U.S. sales of Flomax® capsules were approximately $1.5 billion in the 12 months ended May 2008.

About IMPAX Laboratories, Inc.

IMPAX Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. IMPAX markets its generic products through its Global Pharmaceuticals division and markets its branded products through the IMPAX Pharmaceuticals division. Additionally, where strategically appropriate, IMPAX has developed marketing partnerships to fully leverage its technology platform. IMPAX Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. For more information, please visit the Companys Web site at:

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

To the extent any statements made in this news release contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause IMPAXs future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, possible adverse effects resulting from the delisting of and suspension of trading in IMPAXs stock, IMPAXs failure to file any periodic reports subsequent to its quarterly report on Form 10-Q for the quarter ended September 30, 2004, the SECs revocation of the registration of IMPAXs common stock under section 12 of the Securities Exchange Act of 1934, the actual time that will be required to file a registration statement on Form 10 with respect to such stock, IMPAXs ability to obtain sufficient capital to fund its operations, the difficulty of predicting FDA filings and approvals, consumer acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, IMPAX's ability to successfully develop and commercialize pharmaceutical products, IMPAXs reliance on key strategic alliances, the uncertainty of patent litigation, the availability of raw materials, the regulatory environment, dependence on patent and other protection for innovative products, exposure to product liability claims, fluctuations in operating results and other risks detailed from time to time in IMPAXs filings with the Securities and Exchange Commission. Forward-looking statements speak only as to the date on which they are made, and IMPAX undertakes no obligation to update publicly or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.


Company Contacts:
IMPAX Laboratories, Inc.
Larry Hsu, Ph.D. President & CEO
(510) 476-2000, Ext. 1111
Arthur Koch, CFO
(215) 933-0351
Mark Donohue, Sr. Director IR
(215) 933-3526
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz
(212) 838-3777
Bruce Voss
(310) 691-7100